A constipation drug, repurposed: small trial points to a new lever on the cognitive haze that follows depression
A small UK trial of prucalopride, already approved for chronic constipation, suggests measurable gains in memory and attention among people with a history of depression. Researchers caution that the cognitive effect, not the mood effect, is what's new.
On 16 July 2026, a research team at King's College London reported that prucalopride, a tablet already prescribed for chronic constipation, produced measurable improvements in memory and concentration in adults with a history of major depression, even when their mood scores were already stable. The finding, presented at the Alzheimer's Association International Conference in London, lands in a part of medicine where progress has been stubbornly incremental: the residual cognitive symptoms that follow a depressive episode and that conventional antidepressants rarely touch.
The work matters less for the drug itself than for the lever it pulls. Prucalopride activates a serotonin receptor, 5-HT4, that is abundant in brain regions tied to learning and recall. Repurposing an approved medicine sidesteps the long, expensive road from animal models to first-in-human safety data. It also repositions a problem most patients describe as "brain fog" from a soft complaint into a measurable, drug-addressable deficit.
What the trial actually showed
The phase 2 study enrolled adults whose depression was in remission but who continued to report slow thinking, poor word recall and difficulty concentrating. Participants were randomised to prucalopride or placebo for six weeks. The headline outcome was cognitive, not mood: standardised tests of verbal learning, working memory and attention. According to the researchers, the drug arm outperformed placebo on those measures within days, a speed of onset that surprised even the investigators. Self-reported mood did not change, which the team treats as the point: the cognitive lift appears to ride on a different mechanism than conventional antidepressants.
The mechanism matters because it points at the receptor rather than at serotonin reuptake. Prucalopride is a selective 5-HT4 agonist, designed originally to stimulate gut motility. Its action in the central nervous system had been documented in earlier small studies, including work in Parkinson's disease dementia and a separate depression trial, but the new King's College dataset is the first randomised evidence large enough to register on regulators' radar.
The counter-narrative: small trial, big claim
The size of the trial is the obvious objection. The patient cohort was in the dozens, recruited at a single academic centre, and the cognitive battery, while standardised, is not the same as a daily-functioning measure. Critics will note that cognitive performance on a clinic-day test can move on attention, motivation or even sleep quality the night before, without any genuine change in underlying neural processing. The investigators acknowledge the limitation and are clear that the next step is a multi-site phase 2b in a larger, more clinically diverse cohort.
A second line of caution runs through the broader field. Drug repurposing in psychiatry has a mixed record. Established compounds from other specialties, including anaesthetics and antihistamines, have produced promising early signals in depression and cognition only to stall in larger trials. The pattern has cooled investor and funder enthusiasm for the entire category, which makes the King's College result both more interesting and harder to fund into the next phase.
A structural shift in how psychiatric drugs get developed
The more durable story may sit one level above the molecule. Repurposing is a quiet but consequential restructuring of psychiatric drug development. The traditional path, identify a target in rodent brains, optimise a molecule, run a decade of safety and efficacy trials, has produced diminishing returns: the most prescribed antidepressants today were discovered before the end of the Cold War. New approvals have slowed while the global burden of depression has grown.
Prucalopride's path, starting from a known receptor, a known safety profile, an existing commercial supply chain and a regulator already comfortable with the molecule, compresses the timeline and the cost. It also reframes the scientific question. Instead of "does this new molecule treat depression?", the field is increasingly asking "which of the receptors already targeted by approved drugs also shape mood and cognition?". That is a different research programme, with different commercial logic, and it has begun to reshape pipelines at large pharmaceutical companies and at the UK's translational institutes in particular.
Stakes: who pays, who benefits, what to watch next
The immediate stakes are scientific and competitive. A successful phase 2b would put prucalopride, off-patent in some markets and marketed by Takeda as Resolor, at the centre of a race among smaller biotechs and academic groups working on adjacent serotonergic targets. Larger pharmaceutical firms, already burned by failed late-stage depression programmes, will watch the cognitive endpoint carefully: a clean win on memory and attention in a remitted population would reopen a market that has treated cognitive symptoms as essentially unreachable.
Patients have the most to gain and the least leverage. The cognitive residue of depression, often called brain fog, is the symptom most likely to keep people out of work after their mood has recovered, and the symptom for which clinicians have the fewest evidence-based tools. A repurposed constipation drug will not solve that, and the trial's own authors are explicit about the distance between a positive signal at one centre and a clinical recommendation. But for the first time in some years, a lever in the brain's serotonin system other than reuptake has moved on the cognitive side of the ledger in a randomised human trial, and that is the headline worth tracking.
The next data point to watch is the planned multi-site phase 2b, expected to begin enrolment in late 2026, with first readouts likely in 2027. If the cognitive effect survives a larger, more representative cohort, regulators will face a question that does not yet have a tidy answer: how to label a medicine that improves cognition in remitted depression without claiming to treat depression itself.
Monexus framed this as a receptor-mechanism story first and a depression story second, reflecting the investigators' own emphasis on the cognitive endpoint rather than mood.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://t.me/sciencenewsfx/1
- https://en.wikipedia.org/wiki/Prucalopride
- https://en.wikipedia.org/wiki/5-HT4_receptor
- https://en.wikipedia.org/wiki/Alzheimer%27s_Association_International_Conference